Annals of Oncology Advance Access originally published online on February 9, 2006
Annals of Oncology 2006 17(4):578-583; doi:10.1093/annonc/mdl009
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
1 Centre Pluridisciplinaire d'Oncologie and 4 Département de Chirurgie, University of Lausanne Hospitals (CHUV), Lausanne, Switzerland; 2 Hôpital Ophtalmique Jules Gonin, Lausanne, Switzerland; 3 ForMed, Evolène, Switzerland; 5 Ospedale Generale San Giuseppe, Empoli, Italy; 6 Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel; 7 Sheba Medical Center, Tel Hashomer, Israel; 8 Medizinische Klinik II, Benjamin Franklin Hospital of the Free University, Berlin, Germany; 9 Centre du Cancer, St Luc University Hospital, Brussels, Belgium; 10 Institut Curie, Paris, France
* Correspondence to: Dr S. Leyvraz, Multidisciplinary Oncology Center, University of Lausanne Hospitals (CHUV), 46, rue du Bugnon, 1011 Lausanne, Switzerland. Tel: +41-21-314-0149; Fax: +41-21-314-0181; E-mail: Serge.Leyvraz{at}hospvd.ch
Background: Exclusive liver metastases occur in up to 40% of patients with uveal melanoma associated with a median survival of 2–7 months. Single agent response rates with commonly available chemotherapy are below 10%. We have investigated the use of fotemustine via direct intra-arterial hepatic (i.a.h.) administration in patients with uveal melanoma metastases.
Patients and methods: A total of 101 patients from seven centers were treated with i.a.h. fotemustine, administered intra-arterially weekly for a 4-week induction period, and then as a maintenance treatment every 3 weeks until disease progression, unacceptable toxicity or patient refusal.
Results: A median of eight fotemustine infusions per patient were delivered (range 1–26). Catheter related complications occurred in 23% of patients; however, this required treatment discontinuation in only 10% of the patients. The overall response rate was 36% with a median overall survival of 15 months and a 2-year survival rate of 29%. LDH, time between diagnosis and treatment start and gender were significant predictors of survival.
Conclusions: Locoregional treatment with fotemustine is well tolerated and seems to improve outcome of this poor prognosis patient population. Median survival rates are among the longest reported and one-third of the patients are still alive at 2 years.
Key words: fotemustine, intra-arterial hepatic chemotherapy, uveal melanoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S Frenkel, I Nir, K Hendler, M Lotem, A Eid, O Jurim, and J Pe'er Long-term survival of uveal melanoma patients after surgery for liver metastases Br J Ophthalmol, August 1, 2009; 93(8): 1042 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yamamoto, I. Chervoneva, K. L. Sullivan, D. J. Eschelman, C. F. Gonsalves, M. J. Mastrangelo, D. Berd, J. A. Shields, C. L. Shields, M. Terai, et al. High-Dose Immunoembolization: Survival Benefit in Patients with Hepatic Metastases from Uveal Melanoma Radiology, July 1, 2009; 252(1): 290 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Meyer, B. B. Frericks, M. Voges, M. Borchert, P. Martus, J. Justiz, K.-J. Wolf, and F. K. Wacker Visualization of Hypervascular Liver Lesions During TACE: Comparison of Angiographic C-Arm CT and MDCT Am. J. Roentgenol., April 1, 2008; 190(4): W263 - W269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsai and J. M. O'Brien The Future Promise and the Current Reality of Genetic Prognostication in Patients With Uveal Melanoma Arch Ophthalmol, March 1, 2008; 126(3): 413 - 415. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Bosch, J. A. Thompson, M. K. Srivastava, U. K. Iheagwara, T. G. Murray, M. Lotem, B. R. Ksander, and S. Ostrand-Rosenberg MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells Cancer Res., May 1, 2007; 67(9): 4499 - 4506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schuster, N. E. Bechrakis, A. Stroux, A. Busse, A. Schmittel, C. Scheibenbogen, E. Thiel, M. H. Foerster, and U. Keilholz Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma Clin. Cancer Res., February 15, 2007; 13(4): 1171 - 1178. [Abstract] [Full Text] [PDF]
|
|